%0 Journal Article
%A Pérez-Gómez, Alberto
%A Vitallé, Joana
%A Gasca-Capote, Carmen
%A Gutierrez-Valencia, Alicia
%A Trujillo-Rodriguez, María
%A Serna-Gallego, Ana
%A Muñoz-Muela, Esperanza
%A Jiménez-Leon, María de Los Reyes
%A Rafii-El-Idrissi Benhnia, Mohamed
%A Rivas-Jeremias, Inmaculada
%A Sotomayor, Cesar
%A Roca-Oporto, Cristina
%A Espinosa, Nuria
%A Infante-Domínguez, Carmen
%A Crespo-Rivas, Juan Carlos
%A Fernández-Villar, Alberto
%A Pérez-González, Alexandre
%A López-Cortés, Luis Fernando
%A Poveda, Eva
%A Ruiz-Mateos, Ezequiel
%A Virgen del Rocío Hospital COVID-19 Working Team
%T Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection.
%D 2021
%U http://hdl.handle.net/10668/18233
%X Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components. Dendritic cells (DCs) play a key role in the defense against viral infections, for instance plasmacytoid DCs (pDCs), have the capacity to produce vast amounts of interferon-alpha (IFN-α). In COVID-19 there is a deficit in DC numbers and IFN-α production, which has been associated with disease severity. In this work, we described that in addition to the DC deficiency, several DC activation and homing markers were altered in acute COVID-19 patients, which were associated with multiple inflammatory markers. Remarkably, previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+ myeloid DCs and pDCs seven months after SARS-CoV-2 infection. Moreover, the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients, while no restoration of integrin β7 and indoleamine 2,3-dyoxigenase (IDO) levels were observed. These findings contribute to a better understanding of the immunological sequelae of COVID-19.
%K COVID-19
%K Dendritic cell
%K Long-COVID
%K SARS-CoV-2
%~